Leicester

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma5 trials
• Colorectal cancer1 trial
• Endometrial cancer1 trial
• Hepatitis B1 trial
• HIV1 trial
• Prostate cancer1 trial

Phase

• Phase 34 trials
• Phase 12 trials
• Phase 22 trials
• Phase 1/21 trial

Status

• Recruiting4 trials
• Active, not recruiting3 trials
• Completed2 trials

Lead sponsor

• GlaxoSmithKline8 trials
• ViiV Healthcare1 trial

Running trials

• Recruiting

  A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

  NCT07286331· Phase 3· GlaxoSmithKline· Source

  Contact: Joanna Wood (principal investigator)

• Recruiting

  A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

  NCT07277270· Phase 1· GlaxoSmithKline· Source

  Contact: Harriet Walter (principal investigator)

• Recruiting

  A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

  NCT06679101· Phase 3· GlaxoSmithKline· Source

  Contact: Mamta Garg (principal investigator)

• Recruiting

  A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

  NCT05714839· Phase 1/2· GlaxoSmithKline· Source

  Contact: Linda Barton (principal investigator)

• Active, not recruiting

  Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  NCT04246047· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

  NCT04091126· Phase 1· GlaxoSmithKline· Source

• Active, not recruiting

  Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

  NCT02362503· Phase 3· ViiV Healthcare· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma2 recruiting
• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy

  NCT05276297· Phase 2· GlaxoSmithKline· Source

• Completed

  Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05064358· Phase 2· GlaxoSmithKline· Source